Atara Biotherapeutics (ATRA): Analyst Targets Point to +71% Upside Potential

Key Takeaways

• The central $14 stock price target is the arithmetic mean of three verified analyst price targets, rounded from an underlying mean of roughly $13.67.
• With ATRA recently trading near $8.20, reaching $14 would require a rise of about 71%, a very large move.
• The three current analyst targets span a wide $10 to $18 range, split between two Buy ratings and one Hold, reflecting disagreement over the company's strategic and regulatory outlook.
• The strongest support is the U.S. FDA's acceptance of the resubmitted tabelecleucel (tab-cel) application, with a PDUFA target action date of March 31, 2027.
• The biggest risks are a thin cash position of about $9.9 million, a prior FDA rejection, a shareholders' equity deficit, and a newly filed $200 million shelf registration that could dilute holders.
• For more detail on this ticker's latest developments, visit the Major News, Today's Price Move, Forecast, and Earnings pages.

Analyst Consensus and Price Targets

Atara Biotherapeutics, Inc. (ATRA) is a clinical-stage T-cell immunotherapy company, best known for developing the first allogeneic T-cell therapy to win regulatory approval. The company's shares carry a thin but genuine analyst footprint: three current targets were reviewed to build the central figure. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The individual targets are Canaccord Genuity (John Newman) at $13 with a Buy rating, Mizuho Securities (Salim Syed) at $18 with a Buy rating, and Freedom Capital Markets at $10 with a Hold rating following an upgrade from Sell. The low-to-high range is therefore $10 to $18. Averaging these three values produces a mean of about $13.67, which is rounded to a clean $14 central target.

This spread is unusually wide relative to the share price, and it matters: it signals that analysts disagree on how much of the tab-cel opportunity Atara will actually capture. Mizuho's higher target reflects confidence in the drug's U.S. potential and reduced operating expenses, while the lower Freedom Capital target reflects a more cautious stance on the company's financial position. No analyst target here is a guarantee, and the mean is best read as a midpoint of a contested outlook rather than a firm forecast.

Current Market Position and Path Toward the Target

Atara's shares recently traded near $8.20, toward the lower half of a 52-week range of roughly $3.92 to $19.15, with a market capitalization of about $81 million. Reaching the $14 central target from that level implies upside of roughly 71%, a very large move by any standard and one that would require a material re-rating of the company's risk profile.

The likely path runs through the regulatory calendar. The FDA issued a Complete Response Letter in January 2026 on the original tab-cel biologics license application (BLA), but Atara resubmitted the filing and the agency accepted it in October 2026, setting a PDUFA (Prescription Drug User Fee Act) target action date of March 31, 2027. Under Atara's commercialization agreement with Pierre Fabre Laboratories, U.S. approval would trigger a $31 million milestone payment plus double-digit tiered royalties on net sales. That single event is the clearest catalyst that could compress the gap toward the $14 level.

What Could Support a Move Toward the Target

• FDA acceptance and a defined review date. A resubmitted BLA that is under active review, with a March 31, 2027 PDUFA date, gives the investment thesis a concrete, near-term binary catalyst.
• Contingent economics. Approval would unlock a $31 million milestone and tiered royalties from Pierre Fabre, a meaningful sum relative to Atara's roughly $81 million market cap.
• Cost discipline. Third-quarter 2026 operating expenses fell sharply year over year, and the company says its cash should fund operations into mid-2027.
• Institutional interest. Several funds added to positions in 2026, suggesting some investors see value in a potential approval scenario.

What Could Prevent the Target From Being Reached

• Balance-sheet fragility. Cash, equivalents, and short-term investments totaled about $9.9 million at September 30, 2026, and the company carries a stockholders' equity deficit of roughly $38 million.
• Regulatory history. The January 2026 Complete Response Letter remains a reminder that the FDA review is not assured to end in approval.
• Dilution risk. A $200 million mixed securities shelf filed in November 2026 could raise capital but also dilute existing shareholders.
• Limited revenue. Third-quarter 2026 revenue was only $1.2 million, with a net loss of $2.2 million, leaving the stock heavily dependent on milestone payments and financing.

Technical Levels and Market Structure

Atara's shares sit below their roughly $9.02 50-day moving average but above the 200-day average near $7.80, a mixed structure that places near-term resistance just overhead and longer-term support beneath. The $9 area and the prior high near $19.15 represent the most meaningful overhead zones, while the 52-week low near $3.92 marks the floor in the current cycle. Any sustained move toward $14 would first need to clear the $9–$10 region, which coincides with the lowest of the three analyst targets.

Time Horizon and What Investors Should Monitor

Analyst price targets for a company like Atara generally reflect a research horizon of roughly 12 months, though the specific horizons are not disclosed for every target and should not be assumed. The single most important date on the calendar is the March 31, 2027 PDUFA target action date for tab-cel. Around that, investors should watch quarterly cash and runway updates, any capital raises under the shelf registration, and analyst revisions tied to the FDA review. Because Pierre Fabre—not Atara—controls the BLA and its FDA interactions, commentary from the partner is also worth monitoring.

Final Assessment

The $14 central target is a rounded average of three analyst price targets spanning $10 to $18, and it sits about 71% above Atara's recent price near $8.20. Reaching it would require a very large re-rating, and the realistic path depends overwhelmingly on a successful FDA review of tab-cel by the March 2027 PDUFA date and the milestone and royalty economics that would follow. Against that upside sits a genuine risk set: limited cash, a prior rejection, an equity deficit, and potential dilution. Analyst disagreement is wide for a reason, and no outcome is assured. Investors should watch the regulatory calendar, cash runway, and financing activity above all else.

Using Tickeron AI Daily Buy/Sell Signals

In my analysis of event-driven names like this, Tickeron's AI Daily Buy/Sell Signals have been a helpful resource. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile stock such as Atara, these signals can help identify opportunities, track existing positions, and spot shifting trends more efficiently than manual scanning. I find it particularly useful when monitoring regulatory catalysts and technical levels in real time.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume